The Food and Drug Administration (FDA) has approved updated labeling for Unloxcyt™ (cosibelimab-ipdl) for the treatment of adults with metastatic ...

The FDA is expected to decide on treatments for breast cancer, EBV+ post-transplant lymphoproliferative disease, focal segmental glomerulosclerosis, presbyopia, and severe allergic reactions.

HealthDay News — Millions of people rely on continuous glucose monitors to help manage diabetes. But a new alert from the Food and Drug Administration (FDA) warns that some sensors from Abbott may ...

Avance is a nerve allograft derived from the nerve tissue of cadavers. It is used to restore peripheral nerve function following injury by bridging the gaps in damaged nerves. To reduce the risk of ...

Following the expanded approval, the accelerated approval for the later-line CLL/SLL was converted to a traditional approval.

Higher risk for overdose seen with lower adherence for 12 months, discontinuation in three to nine months, discontinuation in less than three months ...

HealthDay News — For the first time in more than 3 decades, the US did not take part in World AIDS Day on December 1, a major change from past years when the day was used to raise awareness about ...

HealthDay News — More than 69% of Medicaid enrollees with a new diagnosis of opioid use disorder (OUD) do not receive treatment within 180 days, according to a study published online November 23 in ...

HealthDay News — A confidential internal memo from the US Food and Drug Administration (FDA) is creating new controversy around vaccine safety after an agency official said the COVID-19 vaccine may ...

Omlyclo was originally approved in March 2025 in 2 single-dose prefilled syringe strengths: 75mg/0.5mL and 150mg/mL.

Deucrictibant is an oral, small-molecule antagonist that inhibits the bradykinin signaling pathway through the bradykinin B2 receptor.

The Company plans to submit its response to the CRL, including the results from the HOPE-3 trial, to address the Agency's previous requests for additional data.